Klacid

Clarithromycin, the active ingredient in Klacid, is a macrolide antibiotic presented as an oral tablet for systemic use. It treats a range of bacterial infections, including respiratory, skin and soft‑tissue, and Helicobacter pylori‑related conditions, in adult and pediatric patients where appropriate.

GNH USA supplies Klacid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution. Our supply chain supports timely delivery to both private and public healthcare institutions across Europe, Asia and the Americas.

Clarithromycin is a macrolide antibiotic used to treat bacterial infections of the respiratory and other systems.

- Community‑acquired pneumonia: reduces bacterial load and improves clinical outcomes in adults. - Acute bacterial sinusitis: eradicates the causative pathogens and relieves sinus inflammation. - Acute exacerbations of chronic bronchitis: shortens symptom duration and prevents further lung damage. - Skin and soft‑tissue infections: eliminates susceptible Gram‑positive and some Gram‑negative organisms. - Helicobacter pylori eradication: part of combination therapy to achieve bacterial clearance and ulcer healing.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: frequent loose stools, often self‑limiting. - Abdominal pain: cramping or discomfort in the stomach area. - Taste disturbance: altered or metallic taste perception. - Headache: transient mild to moderate headache. - Rash: mild skin erythema or itching.

Serious or Rare Side Effects: - Clostridioides difficile‑associated diarrhea: severe colitis requiring medical attention. - Hepatotoxicity: elevated liver enzymes or jaundice. - QT interval prolongation: risk of cardiac arrhythmias. - Severe allergic reactions: anaphylaxis, angioedema. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: life‑threatening skin reactions. - Hepatic necrosis: rare but potentially fatal liver injury.

Before prescribing clarithromycin, clinicians should consider several safety aspects.

- Assess renal function: adjust therapy in severe renal impairment. - Monitor liver enzymes: use caution in patients with hepatic disease. - Avoid in known macrolide hypersensitivity: discontinue if allergic reaction occurs. - Use with caution in patients with QT prolongation: monitor cardiac rhythm. - Pregnancy category B: generally safe but prescribe only when benefit outweighs potential risk. - Store at room temperature: keep in original container, protect from moisture and heat.

Clarithromycin can alter the plasma concentrations of several co‑administered drugs.

Major Interactions (Avoid): - Simvastatin: increased risk of rhabdomyolysis. - Pimozide: heightened risk of arrhythmia. - Ergot alkaloids: possible severe vasospasm. - Cisapride: risk of life‑threatening QT prolongation.

Moderate Interactions (Monitor Closely): - Warfarin: enhanced anticoagulant effect, monitor INR. - Theophylline: elevated serum levels, watch for toxicity. - Digoxin: increased concentrations, assess cardiac function. - Antacids containing aluminum or magnesium: may reduce clarithromycin absorption.